© 2016

Biologics to Treat Substance Use Disorders

Vaccines, Monoclonal Antibodies, and Enzymes

  • Ivan D. Montoya

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Vaccines

    1. Front Matter
      Pages 5-5
    2. Coreen B. Domingo, Daryl Shorter, Thomas R. Kosten
      Pages 25-36
    3. Michael D. Raleigh, Paul R. Pentel
      Pages 37-63
    4. Thomas R. Kosten, Therese A. Kosten
      Pages 65-74
    5. Timothy Cardozo, Sergey V. Shmelkov, Kenneth Carr, John Rotrosen, Pedro Mateu-Gelabert, Samuel R. Friedman
      Pages 75-103
  3. Monoclonal Antibodies

    1. Front Matter
      Pages 105-105
    2. S. Michael Owens
      Pages 107-108
    3. Hanna N. Wetzel, William J. Ball, Andrew B. Norman
      Pages 109-117
    4. Michael D. Hambuchen, Misty W. Stevens, Melinda G. Gunnell, W. Brooks Gentry, S. Michael Owens
      Pages 119-142
  4. Enzymes

    1. Front Matter
      Pages 143-143
    2. W. Stephen Brimijoin
      Pages 167-185
    3. Fang Zheng, Chang-Guo Zhan
      Pages 187-225
  5. Strategies to Optimize the Development of Biologics to Treat Addictions

    1. Front Matter
      Pages 227-227
    2. David F. Havlicek, Jonathan B. Rosenberg, Dolan Sondhi, Ronald G. Crystal, Stephen M. Kaminsky
      Pages 229-248
    3. Petr O. Ilyinskii, Lloyd P. M. Johnston
      Pages 249-278
    4. Xiaowei Liu, Sidney M. Hecht, Hao Yan, Paul R. Pentel, Yung Chang
      Pages 279-293

About this book


This book is a scientific compendium documenting the state of the art in the discovery and development of vaccines, monoclonal antibodies, and enzymes for the treatment of Substance Use Disorders (SUDs). The book gives detailed consideration to some of the most cutting edge topics in addiction medicine, including vaccines for nicotine, cocaine, heroin, and methamphetamine dependence; monoclonal antibodies against cocaine, methamphetamine, and phencyclidine; and the enzymes butyrylcholinesterase and cocaine esterase. In addition, the text covers a wide range of new strategies designed to optimize the development and efficacy of biologics. Unlike any other resource, this book reviews how biologics offer exciting new therapeutic opportunities for various psychiatric conditions.

Written by experts in the field, Biologics to Treat Substance Use Disorders is as an authoritative reference for psychiatrists, psychologists, and all other medical professionals working with patients suffering from Substance Use Disorders.


Biologics Drug Addiction Enzymes Monoclonal Antibodies Substance Abuse Vaccines

Editors and affiliations

  • Ivan D. Montoya
    • 1
  1. 1.National Institute on Drug AbuseNational Institutes of HealthBethesdaUSA

About the editors

Ivan D. Montoya
National Institutes of Health, 
Bethesda, USA

Bibliographic information

  • Book Title Biologics to Treat Substance Use Disorders
  • Book Subtitle Vaccines, Monoclonal Antibodies, and Enzymes
  • Editors Ivan D. Montoya
  • DOI
  • Copyright Information Springer International Publishing Switzerland 2016
  • Publisher Name Springer, Cham
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-3-319-23149-5
  • Softcover ISBN 978-3-319-79451-8
  • eBook ISBN 978-3-319-23150-1
  • Edition Number 1
  • Number of Pages XVI, 453
  • Number of Illustrations 47 b/w illustrations, 57 illustrations in colour
  • Topics Psychopharmacology
  • Buy this book on publisher's site
Industry Sectors


“The intended audience is psychiatrists, pharmacologists, immunologists, counselors, toxicologists, social workers, addiction specialists, and all medical professionals working with patients with drug addictions. … This is the first book, and a most comprehensive one, about the research and development of biologics to treat substance use disorders and overdose. Hopefully, biologics will be part of the therapeutic armamentarium that healthcare providers can use in the treatment of their patients with these disorders.” (Michael Easton, Doody's Book Reviews, June, 2016)